Testing Intranasal Scopolamine Gel for Motion Sickness Relief in Astronauts and Operational Personnel Evaluating Effectiveness and Ease of Use During Spaceflight and Motion Simulations

What this Trial Is About

Researchers are evaluating the use of intranasal scopolamine gel DPI-386 to help reduce motion sickness and improve sensorimotor performance. This study involves both astronauts on space missions and ground-control participants exposed to motion such as centrifuge training, parabolic flights, and capsule recovery operations. The goal is to test the medications feasibility and effectiveness in real operational settings, with astronauts from missions like SpaceX Polaris Dawn, Axiom, and the International Space Station. Participants will self-administer a 0.4 mg dose of intranasal scopolamine gel during training and operational exposures to motion. They will learn to apply the medication in a 15-minute training session and complete debriefs about symptoms, side effects, and ease of use. Astronauts may take the drug before or after motion exposure to prevent or treat symptoms. Control participants may use other motion sickness medications such as promethazine or meclizine. Both groups will complete surveys before, during, and after exposure to capture symptom severity and medication effectiveness. Throughout the study, participants will complete questionnaires on motion sickness symptoms, side effects, and medication feasibility. Surveys will track symptoms daily during and after exposure, including nausea, vertigo, headache, and drowsiness. Researchers will measure motion sickness using the Pensacola Diagnostic Index nausea scale and assess symptom impact on functional tasks. The study includes a one-week monitoring period for outcome measures, with data collected on medication use and recovery recommendations.

Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance